CCO

Cortechs.ai Appoints Kyle Frye as New Chief Executive Officer

Retrieved on: 
Wednesday, April 3, 2024
Growth, Northern Kentucky University, CFO, Patient, CCO, SAN, Smith, Radiology, Brainlab, AI, Cancer, Nate White, Smith & Nephew, Siemens Healthineers, FDA, Health, DSM-IV codes, Nursing

SAN DIEGO, April 3, 2024 /PRNewswire/ -- Cortechs.ai, a leading innovator in AI applications for radiology and the developer of FDA-cleared products for the improved detection of neurodegenerative diseases and cancer, is excited to announce the appointment of Kyle Frye as its new Chief Executive Officer.

Key Points: 
  • SAN DIEGO, April 3, 2024 /PRNewswire/ -- Cortechs.ai, a leading innovator in AI applications for radiology and the developer of FDA-cleared products for the improved detection of neurodegenerative diseases and cancer, is excited to announce the appointment of Kyle Frye as its new Chief Executive Officer.
  • Prior to SyntheticMR, Kyle served as a Vice President of Sales at Siemens Healthineers, demonstrating his capability to lead high-performing teams and drive significant sales growth.
  • Kyle holds a bachelor's degree from Northern Kentucky University and is a proud resident of the Cincinnati metro area.
  • I am excited to be part of this amazing team and to be able to work closely with our customers and patients on a daily basis," said Kyle Frye.

Royer Cooper Cohen Braunfeld and 3iCO, LLC Launch Joint Venture

Retrieved on: 
Wednesday, April 3, 2024
Risk management, Partner (business rank), AML, General counsel, Knowledge, Senior counsel, CCO, Private law, Conshohocken, Pennsylvania, FINRA, Financial adviser

PHILADELPHIA, April 3, 2024 /PRNewswire-PRWeb/ -- Royer Cooper Cohen Braunfeld LLC (RCCB), a law firm offering a distinctive combination of practical business acumen, legal expertise and entrepreneurial passion, today announced a joint venture between the firm's partners and 3iCO, LLC, a provider of compliance consulting and outsourced Chief Compliance Officer (CCO) services. This new venture enables RCCB to cater more efficiently to regulatory compliance matters for its investment management, fund, and broker-dealer clients.

Key Points: 
  • This new venture enables RCCB to cater more efficiently to regulatory compliance matters for its investment management, fund, and broker-dealer clients.
  • RCCB's Managing Partner, John E. Royer, Jr., will serve as 3iCO's Chairman, while RCCB co-founder, Roger J. Braunfeld, will also serve on the Board with Laura and Justin.
  • Additionally, this joint venture provides another layer of expertise to which we can refer applicable clients as needs arise."
  • "I am thrilled to launch this joint venture with RCCB," said Flanagan.

PixCell Medical Partners with Healthcare Giants Medline, Henry Schein, and Fisher Scientific to Distribute HemoScreen Point of Care CBC Analyzer Across the USA

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Analyser, Complete blood count, Partnership, Thermo Fisher Scientific, CBC, Medline Industries, MEDLINE, Laboratory, Workflow, CCO, Health, Medical device

The partnership with Henry Schein, a global leader in healthcare solutions, will leverage the company's extensive distribution network to make the HemoScreen analyzer readily available to healthcare professionals nationwide.

Key Points: 
  • The partnership with Henry Schein, a global leader in healthcare solutions, will leverage the company's extensive distribution network to make the HemoScreen analyzer readily available to healthcare professionals nationwide.
  • Additionally, Thermo Fisher Scientific, renowned for its scientific expertise and comprehensive product offerings, will contribute to broadening the reach of the HemoScreen analyzer within the scientific research and laboratory community.
  • "We are thrilled to join forces with Henry Schein, Medline, and Thermo Fisher Scientific to bring the HemoScreen point-of-care CBC analyzer to healthcare providers and laboratories throughout the United States," said Guy Frak, CCO of PixCell Medical.
  • Through these collaborations, PixCell Medical remains dedicated to advancing healthcare delivery by making cutting-edge diagnostic technology accessible and affordable across diverse healthcare settings.

LOBOS 1707 TEQUILA PARTNERS WITH (RED) TO LAUNCH A LIMITED-EDITION REPOSADO BOTTLE TO SUPPORT LIFE-SAVING PROGRAMS THAT FIGHT AIDS

Retrieved on: 
Tuesday, April 2, 2024
AIDS, Partnership, RED, Ageing, Global health, Sherry, Mark R. Dybul, CCO, LOBOS, Wine, LeBron James, Solera, Tequila, PX

NEW YORK, April 2, 2024 /PRNewswire/ -- Today, Lobos 1707 Tequila & Mezcal, the ultra-premium agave spirit brand, announces the launch of their (LOBOS 1707)RED Limited-Edition Reposado Tequila in partnership with (RED).

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- Today, Lobos 1707 Tequila & Mezcal, the ultra-premium agave spirit brand, announces the launch of their (LOBOS 1707)RED Limited-Edition Reposado Tequila in partnership with (RED).
  • Through the partnership, Lobos 1707 has committed to contribute $100,000 to the Global Fund to help strengthen global healthcare systems and fund life-saving programs in vulnerable communities.
  • Lobos 1707 Tequila & Mezcal was established as an independent spirits producer in 2020 by Founder and Chief Creative Officer, Diego Osorio, with investor, legendary athlete, and cultural icon LeBron James.
  • Lobos 1707's award-winning Reposado has been developed into a Limited-Edition (RED)-themed bottle, presenting its same ultra-premium bold liquid tied to this bolder mission to end AIDS.

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on: 
Tuesday, April 2, 2024
Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points: 
  • LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
  • The Company will publish Q1 2024 results on April 18, 2024.
  • The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on: 
Tuesday, April 2, 2024
Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points: 
  • LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
  • The Company will publish Q1 2024 results on April 18, 2024.
  • The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.

Augusta Sportswear Brands and Founder Sport Group Launch New Corporate Identity

Retrieved on: 
Friday, March 29, 2024
CIO, Organization, FSG, Business development, ASB, Senior, CCO, CHRO, Marketing, Platinum Equity, Vice, Management

CHARLOTTE, N.C., March 29, 2024 /PRNewswire/ -- Augusta Sportswear Brands ("ASB") and Founder Sport Group ("FSG") today announced the combined company's new corporate identity, Momentec Brands, and tagline "Outfitting Moments that Matter."

Key Points: 
  • CHARLOTTE, N.C., March 29, 2024 /PRNewswire/ -- Augusta Sportswear Brands ("ASB") and Founder Sport Group ("FSG") today announced the combined company's new corporate identity, Momentec Brands, and tagline "Outfitting Moments that Matter."
  • Momentec Brands emerges as a leading supplier of team uniforms, off-field performance wear and fan apparel tailored for the youth and recreational sports markets.
  • "We are excited to announce the rebranding of the combined company as Momentec Brands.
  • I look forward to continuing to support John and the executive leadership team as Vice Chairman, building on the strong Momentec Brands foundation."

Cypress Creek Renewables Appoints Jeremy Wodakow Chief Commercial Officer

Retrieved on: 
Thursday, March 28, 2024
Axpo Holding, O&M, Fleet, CCO, Risk management

DURHAM, N.C., March 28, 2024 /PRNewswire/ -- Cypress Creek Renewables is pleased to announce that Jeremy Wodakow has taken on the role of Chief Commercial Officer (CCO).

Key Points: 
  • DURHAM, N.C., March 28, 2024 /PRNewswire/ -- Cypress Creek Renewables is pleased to announce that Jeremy Wodakow has taken on the role of Chief Commercial Officer (CCO).
  • In this expanded role, he will now oversee Cypress Creek Solutions, which manages the company's 2.2GW operating Fleet and provides operation and maintenance services to 5GW of solar and storage assets.
  • Wodakow joined the Cypress Creek executive team in February 2023 as Chief Revenue Officer (CRO), focused on contracting development projects to drive commercialization and developing a trading and risk management team to optimize the company's growing portfolio of operating assets.
  • "Jeremy has assembled a top-notch revenue team poised to best meet the needs of our offtake customers," Sarah Slusser, CEO of Cypress Creek, said.

Axiom Health Expands Leadership Team to Accelerate Growth

Retrieved on: 
Thursday, March 28, 2024
Komodo, CIO, Growth, Health, SAN, Pharmacy automation, McKesson Corporation, CCO, Integra LifeSciences, Marketing

These appointments strengthen Axiom Health's leadership capabilities as the company seeks to expand its market presence and deliver enhanced value to its clients.

Key Points: 
  • These appointments strengthen Axiom Health's leadership capabilities as the company seeks to expand its market presence and deliver enhanced value to its clients.
  • His expertise in healthcare technology and his track record of driving innovation will be instrumental in guiding Axiom Health's growth trajectory.
  • Mr. Best joins Axiom Health as CCO with over two decades of experience in the healthcare industry, including sales and marketing leadership roles at Stryker, Integra Lifesciences, TriMed and Komodo Health.
  • "We are excited to welcome Rusty and Jim to the Axiom Health team," said Jim Hinrichs, Chairman of the Board.

POSSIBLE ANNOUNCES IMPROBABLE MEDIA CHAIRMAN & ESPN TALENT JAY WILLIAMS

Retrieved on: 
Wednesday, March 27, 2024
Fontainebleau Miami Beach, Culture, ESPN, Chicago Bulls, Autobiography, NBA draft, Intersection, Media, VIP, Duke University, Life, Influence, CCO, Ecosystem, CMO, NBA, Marketing, Advertising

NEW YORK, March 27, 2024 /PRNewswire/ -- Beyond Ordinary Events, Inc. and POSSIBLE, the premier marquee marketing event, announced today the improbable Media Chairman & Co-founder Jay Williams will be joined by Chris Detert and Tammy Henault on stage for a live interview on April 16. The session, titled "The Intersection of Sports, Culture, and Entertainment " will focus on how these three entities reach their ultimate marketing potential through collaboration and dynamic campaign strategies. 

Key Points: 
  • NEW YORK, March 27, 2024 /PRNewswire/ -- Beyond Ordinary Events, Inc. and POSSIBLE , the premier marquee marketing event, announced today the improbable Media Chairman & Co-founder Jay Williams will be joined by Chris Detert and Tammy Henault on stage for a live interview on April 16.
  • "I'm excited for Jay to bring his expertise from the worlds of business, media and being an elite athlete onto the stage at POSSIBLE," said Christian Muche, CEO and Co-Founder of Beyond Ordinary Events & POSSIBLE.
  • Jay is Chairman of Improbable Media, a company he co-founded with NBA superstar Giannis Antetokounmpo.
  • Improbable Media harnesses the power of content and storytelling to support elite talent and brands in developing and expanding their ecosystem.